Corvus Pharmaceuticals, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 28, 2023. This is an annual report, not a standalone Q4 report. Corvus is a clinical-stage biopharmaceutical company with no product sales and one reportable segment.
Financial and operating highlights
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $24.5 million | $29.1 million |
| General and administrative expense | $8.1 million | $9.5 million |
| Total operating expenses / operating loss | $32.6 million | $38.6 million |
| Net loss | $41.3 million | $43.2 million |
| Net loss per share, basic and diluted | $0.89 | $1.03 |
| Cash used in operating activities | $27.0 million | $36.7 million |
| Cash, cash equivalents and marketable securities, year-end | $42.3 million | $69.5 million |
- Operating expenses declined about 16% year over year. R&D expense fell mainly with lower mupadolimab trial spending and personnel costs; CPI-818 spending increased, including manufacturing costs.
- Net loss narrowed by $1.9 million. The 2022 loss included a $10.0 million equity-method investment loss from Angel Pharmaceuticals, versus $4.8 million in 2021.
- Cash and cash equivalents were $13.2 million and marketable securities were $29.1 million at year-end. Investing activities used $23.3 million, principally reflecting purchases of marketable securities; financing activities provided no cash in 2022.
- Total liabilities were $12.1 million, including operating lease liabilities; the filing reports no borrowings or other debt. Year-end stockholders’ equity was $56.1 million. Profit margins are not meaningful because Corvus has no revenue.
- Management said available resources were expected to fund planned operations for at least 12 months from issuance of the financial statements, but not to complete all development through commercialization. The company expects to need additional capital.
Business, clinical programs and material changes
- CPI-818: ITK inhibitor in a Phase 1/1b trial for refractory T-cell lymphomas. At the February 23, 2023 cutoff, 20 patients had enrolled in the 200 mg cohort and 13 were evaluable; reported responses included complete responses and a partial response. The company also reported a potential absolute lymphocyte count biomarker: in a small subgroup, 4 of 8 patients above the stated threshold had objective responses, compared with none of 5 below it. These are preliminary clinical findings, not confirmatory evidence.
- Corvus said it planned to request an FDA meeting later in 2023 to discuss the design of a possible registration Phase 3 trial; no trial design or approval is assured. Development of CPI-818 for atopic dermatitis was delayed to conserve cash and focus on oncology.
- Ciforadenant: Being evaluated with ipilimumab and nivolumab in a collaborative Phase 1b/2 first-line metastatic renal-cell-cancer trial, expected to enroll about 60 patients.
- Mupadolimab: Corvus completed its Phase 1/1b trial in 2022 after enrolling more than 115 patients. A potential randomized Phase 2 study was deferred to prioritize other programs and conserve capital. Angel Pharmaceuticals is continuing a Phase 1 program in China.
- Corvus holds approximately 49.7% of Angel, which is accounted for under the equity method; Angel’s investment proceeds are not available to fund Corvus. Corvus recorded a $10.0 million share of Angel’s 2022 loss.
Outlook, risks and unusual items
- Corvus expects continued operating losses and has never generated revenue from product sales. Its ability to advance programs depends on additional financing, which may be unavailable or may dilute shareholders, add repayment obligations, or require partnering away rights.
- Key risks include uncertain clinical outcomes and timelines, patient enrollment, regulatory requirements, reliance on third-party manufacturers and trial providers, competition, and the possibility that foreign trial data may not be accepted by U.S. regulators.
- The company reported no material litigation. Potential milestone payments under licenses are contingent and not recorded as current liabilities; disclosed potential amounts include approximately $220 million to Vernalis and $45.1 million to Monash.
- Corvus received a Nasdaq notice in October 2022 regarding the minimum $1.00 bid-price requirement, with a stated compliance deadline of April 24, 2023. The filing does not establish the subsequent outcome.
- The 2020 net loss was only $6.0 million despite a $43.8 million operating loss, primarily because of a one-time $37.5 million gain on deconsolidating Angel. The company reported no comparable gain in 2021 or 2022.
Important facts for investors to verify
- Updated cash runway, financing activity and any subsequent capital raises after the March 2023 filing.
- Latest CPI-818 patient counts, confirmed response durations, biomarker validation, and FDA feedback on any pivotal-trial plan.
- Enrollment, safety and efficacy progress in the ciforadenant and Angel Pharmaceuticals trials, and any changes to Corvus’s development priorities.
- Nasdaq listing compliance status and the company’s capacity to fund trials without substantial dilution or reduced development activity.
- Angel’s financial condition and Corvus’s equity-method investment exposure; also monitor contingent license milestones and manufacturing commitments.